{"id":40232,"date":"2025-08-27T14:27:41","date_gmt":"2025-08-27T06:27:41","guid":{"rendered":"https:\/\/flcube.com\/?p=40232"},"modified":"2025-08-27T14:27:41","modified_gmt":"2025-08-27T06:27:41","slug":"tyk-medicines-secures-exclusive-distribution-of-ty%e2%80%919591-in-mainland-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40232","title":{"rendered":"TYK Medicines Secures Exclusive Distribution of TY\u20119591 in Mainland China"},"content":{"rendered":"\n<p>China-based  <strong>TYK Medicines, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2410:HKG\">HKG: 2410<\/a>) announced on August 26, 2025, that it has entered into a <em>potential<\/em> exclusive distribution agreement with <strong>Sichuan Huiyu Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688553:SHA\">SHA: 688553<\/a>) for its next\u2011generation tyrosine\u2011kinase inhibitor, <strong>asandeutertinib mesylate tablets (TY\u20119591)<\/strong>.<\/p>\n\n\n\n<p><strong>Deal Structure<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusive distributor<\/strong>: Sichuan Huichenxin Pharmaceutical Co., Ltd., a wholly\u2011owned subsidiary of Sichuan Huiyu, will hold exclusive rights to sell TY\u20119591 in mainland China (excluding Hong Kong, Macau, Taiwan, and overseas markets).<\/li>\n\n\n\n<li><strong>Milestone payment<\/strong>: Up to <strong>RMB\u202f150\u202fmillion<\/strong> may be paid upon achievement of predefined commercial milestones.<\/li>\n\n\n\n<li><strong>Scope<\/strong>: The agreement covers all phases of the product life\u2011cycle, including marketing, sales, and post\u2011marketing surveillance.<\/li>\n<\/ul>\n\n\n\n<p><strong>TY\u20119591: A Brain\u2011Penetrant TKI<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Indication<\/strong><\/td><td>EGFR\u2011mutated non\u2011small cell lung cancer (NSCLC) with brain metastases<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Irreversibly binds EGFR mutations (exon\u202f19\u202fdel, exon\u202f21\u202fL858R, exon\u202f19\u202fdel\/T790M, L858R\/T790M) and crosses the blood\u2011brain barrier<\/td><\/tr><tr><td><strong>Safety profile<\/strong><\/td><td>Modified from osimertinib to allow higher dosing and reduce off\u2011target toxicity<\/td><\/tr><tr><td><strong>Clinical milestone<\/strong><\/td><td>Pre\u2011NDA submitted in China (April\u202f2025)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Implications<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market access<\/strong>: The partnership gives TYK a dedicated, experienced distributor with established commercial channels in mainland China, accelerating time\u2011to\u2011market.<\/li>\n\n\n\n<li><strong>Competitive edge<\/strong>: TY\u20119591\u2019s enhanced safety and brain\u2011penetration position it as a compelling alternative to existing EGFR\u2011TKIs, potentially capturing a sizable share of the growing NSCLC\u2011brain metastasis market.<\/li>\n\n\n\n<li><strong>Revenue upside<\/strong>: The milestone payment structure aligns incentives and could generate significant upside as the drug gains regulatory approval and market traction.<\/li>\n<\/ul>\n\n\n\n<p><strong>Outlook<\/strong><\/p>\n\n\n\n<p>Analysts note that the <em>potential<\/em> nature of the agreement means regulatory, commercial, and pricing approvals remain pending. However, the strategic alignment between TYK\u2019s innovative pipeline and Sichuan Huiyu\u2019s distribution network could catalyze a strong launch in China\u2019s largest oncology market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082601627_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025082601627_c.\"><\/object><a id=\"wp-block-file--media-ef2e28bc-aed5-4e2c-be9c-ff2e08ada354\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082601627_c.pdf\">2025082601627_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082601627_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ef2e28bc-aed5-4e2c-be9c-ff2e08ada354\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based TYK Medicines, Inc. (HKG: 2410) announced on August 26, 2025, that it has entered&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40235,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,1586,400,1198,33,395],"class_list":["post-40232","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-hkg-2410","tag-huiyu-pharmaceutical","tag-sha-688553","tag-tkis-egfr-vegf-btk-etc","tag-tyk-medicines"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>TYK Medicines Secures Exclusive Distribution of TY\u20119591 in Mainland China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011listed TYK Medicines (HKEX:\u202f2410) announced a potential exclusive distribution deal with Sichuan Huiyu Pharmaceutical for its novel EGFR\u2011TKI, TY\u20119591, a brain\u2011penetrant therapy for EGFR\u2011mutated lung cancer. The agreement could bring up to RMB\u202f150\u202fm in milestone payments and positions TY\u20119591 for rapid market entry in mainland China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40232\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TYK Medicines Secures Exclusive Distribution of TY\u20119591 in Mainland China\" \/>\n<meta property=\"og:description\" content=\"China\u2011listed TYK Medicines (HKEX:\u202f2410) announced a potential exclusive distribution deal with Sichuan Huiyu Pharmaceutical for its novel EGFR\u2011TKI, TY\u20119591, a brain\u2011penetrant therapy for EGFR\u2011mutated lung cancer. The agreement could bring up to RMB\u202f150\u202fm in milestone payments and positions TY\u20119591 for rapid market entry in mainland China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40232\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-27T06:27:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2707.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40232#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40232\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"TYK Medicines Secures Exclusive Distribution of TY\u20119591 in Mainland China\",\"datePublished\":\"2025-08-27T06:27:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40232\"},\"wordCount\":304,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40232#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2707.webp\",\"keywords\":[\"Cancer\",\"HKG: 2410\",\"Huiyu Pharmaceutical\",\"SHA: 688553\",\"TKIs (EGFR VEGF BTK etc.)\",\"TYK Medicines\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40232#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40232\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40232\",\"name\":\"TYK Medicines Secures Exclusive Distribution of TY\u20119591 in Mainland China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40232#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40232#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2707.webp\",\"datePublished\":\"2025-08-27T06:27:41+00:00\",\"description\":\"China\u2011listed TYK Medicines (HKEX:\u202f2410) announced a potential exclusive distribution deal with Sichuan Huiyu Pharmaceutical for its novel EGFR\u2011TKI, TY\u20119591, a brain\u2011penetrant therapy for EGFR\u2011mutated lung cancer. The agreement could bring up to RMB\u202f150\u202fm in milestone payments and positions TY\u20119591 for rapid market entry in mainland China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40232#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40232\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40232#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2707.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2707.webp\",\"width\":1080,\"height\":608,\"caption\":\"TYK Medicines Secures Exclusive Distribution of TY\u20119591 in Mainland China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40232#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TYK Medicines Secures Exclusive Distribution of TY\u20119591 in Mainland China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TYK Medicines Secures Exclusive Distribution of TY\u20119591 in Mainland China - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011listed TYK Medicines (HKEX:\u202f2410) announced a potential exclusive distribution deal with Sichuan Huiyu Pharmaceutical for its novel EGFR\u2011TKI, TY\u20119591, a brain\u2011penetrant therapy for EGFR\u2011mutated lung cancer. The agreement could bring up to RMB\u202f150\u202fm in milestone payments and positions TY\u20119591 for rapid market entry in mainland China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40232","og_locale":"en_US","og_type":"article","og_title":"TYK Medicines Secures Exclusive Distribution of TY\u20119591 in Mainland China","og_description":"China\u2011listed TYK Medicines (HKEX:\u202f2410) announced a potential exclusive distribution deal with Sichuan Huiyu Pharmaceutical for its novel EGFR\u2011TKI, TY\u20119591, a brain\u2011penetrant therapy for EGFR\u2011mutated lung cancer. The agreement could bring up to RMB\u202f150\u202fm in milestone payments and positions TY\u20119591 for rapid market entry in mainland China.","og_url":"https:\/\/flcube.com\/?p=40232","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-27T06:27:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2707.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40232#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40232"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"TYK Medicines Secures Exclusive Distribution of TY\u20119591 in Mainland China","datePublished":"2025-08-27T06:27:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40232"},"wordCount":304,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40232#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2707.webp","keywords":["Cancer","HKG: 2410","Huiyu Pharmaceutical","SHA: 688553","TKIs (EGFR VEGF BTK etc.)","TYK Medicines"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40232#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40232","url":"https:\/\/flcube.com\/?p=40232","name":"TYK Medicines Secures Exclusive Distribution of TY\u20119591 in Mainland China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40232#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40232#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2707.webp","datePublished":"2025-08-27T06:27:41+00:00","description":"China\u2011listed TYK Medicines (HKEX:\u202f2410) announced a potential exclusive distribution deal with Sichuan Huiyu Pharmaceutical for its novel EGFR\u2011TKI, TY\u20119591, a brain\u2011penetrant therapy for EGFR\u2011mutated lung cancer. The agreement could bring up to RMB\u202f150\u202fm in milestone payments and positions TY\u20119591 for rapid market entry in mainland China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40232#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40232"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40232#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2707.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2707.webp","width":1080,"height":608,"caption":"TYK Medicines Secures Exclusive Distribution of TY\u20119591 in Mainland China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40232#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"TYK Medicines Secures Exclusive Distribution of TY\u20119591 in Mainland China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2707.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40232"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40232\/revisions"}],"predecessor-version":[{"id":40236,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40232\/revisions\/40236"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40235"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}